Terms: = Liver cancer AND CgA AND Prognosis
34 results:
1. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y; Liao JT; Lin Y; Liu C; Wu ZH; Yu B; Sun S; Yu H; Hui XH; Wu XH; Zhao XM; Wang HJ; Zheng Q; Li Y; Hu ZH; Wang JL
J Dig Dis; 2023; 24(8-9):472-479. PubMed ID: 37596865
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression.
Abe D; Akazawa Y; Yatagai N; Hayashi T; Ueyama H; Mine S; Fukunaga T; Nagahara A; Yao T; Saito T
Virchows Arch; 2023 Sep; 483(3):405-414. PubMed ID: 37581693
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.
Wang Y; Wei X; Ke B; Liu J; Guo Y; Liu Y; Chen Y; Ding T; Wang Y; Meng B; Sun B; Zang F
Histopathology; 2023 Oct; 83(4):631-646. PubMed ID: 37356975
[TBL] [Abstract] [Full Text] [Related]
6. Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.
Ni J; Zhang X; Wang H; Si X; Xu Y; Zhao J; Chen M; Zhang L; Wang M
Thorac Cancer; 2022 Feb; 13(4):539-548. PubMed ID: 34970848
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate.
Chen L; Gnanasegaran G; Mandair D; Toumpanakis C; Caplin M; Navalkissoor S
Endocr Relat Cancer; 2022 Jan; 29(2):111-120. PubMed ID: 34932018
[TBL] [Abstract] [Full Text] [Related]
8. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL
Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859
[TBL] [Abstract] [Full Text] [Related]
9. Α-fetoprotein producing hepatoid gastric adenocarcinoma with neuroendocrine differentiation: A case report.
Li T; Liu T; Wang M; Zhang M
Medicine (Baltimore); 2018 Sep; 97(37):e12359. PubMed ID: 30212993
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
11. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours.
Blažević A; Zandee WT; Franssen GJH; Hofland J; van Velthuysen MF; Hofland LJ; Feelders RA; de Herder WW
Endocr Relat Cancer; 2018 Mar; 25(3):245-254. PubMed ID: 29255095
[TBL] [Abstract] [Full Text] [Related]
12. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
[TBL] [Abstract] [Full Text] [Related]
14. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.
Ito T; Hijioka S; Masui T; Kasajima A; Nakamoto Y; Kobayashi N; Komoto I; Hijioka M; Lee L; Igarashi H; Jensen RT; Imamura M
J Gastroenterol; 2017 Jan; 52(1):9-18. PubMed ID: 27539256
[TBL] [Abstract] [Full Text] [Related]
15. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract] [Full Text] [Related]
16. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
[TBL] [Abstract] [Full Text] [Related]
17. Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma.
Hass HG; Jobst J; Scheurlen M; Vogel U; Nehls O
Anticancer Res; 2015 Apr; 35(4):2021-8. PubMed ID: 25862856
[TBL] [Abstract] [Full Text] [Related]
18. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract] [Full Text] [Related]
19. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract] [Full Text] [Related]
20. [Clinicopathologic features of combined hepatic carcinoma].
He C; Yin HF; Liu P; Zhang Y; Zhang JB
Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):824-8. PubMed ID: 24507101
[TBL] [Abstract] [Full Text] [Related]
[Next]
